EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Barriers to immune cell infiltration in tumors

Marit M Melssen iD, Natasha D Sheybani, Katie M Leick, Craig L Slingluff iD

Journal for ImmunoTherapy of Cancer · 2023-04 · 11 (4) · e006401

DOI: 10.1136/jitc-2022-006401 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.04.2023. Verfasst von Marit M Melssen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 171-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Cancer Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased immune cell infiltration into tumors is associated with improved patient survival and predicts response to immune therapies. Thus, identification of factors that determine the extent of immune infiltration is crucial, so that methods to intervene on these targets can be developed. T cells enter tumor tissues through the vasculature, and under control of interactions between homing receptors on the T cells and homing receptor ligands (HRLs) expressed by tumor vascular endothelium and tumor cell nests. HRLs are often deficient in tumors, and there also may be active barriers to infiltration. These remain understudied but may be crucial for enhancing immune-mediated cancer control. Multiple intratumoral and systemic therapeutic approaches show promise to enhance T cell infiltration, including both approved therapies and experimental therapies. This review highlights the intracellular and extracellular determinants of immune cell infiltration into tumors, barriers to infiltration, and approaches for intervention to enhance infiltration and response to immune therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesNeoplasmsHumansLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

CD8-positive T-lymphocytescytotoxicity, immunologiclymphocytes, tumor-infiltratingtumor microenvironment

Autor:innen und Institutionen

  • Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden.
  • Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Surgery, University of Iowa, Iowa City, Iowa, USA.
  • Surgery, University of Virginia, Charlottesville, Virginia, USA cls8h@virginia.edu.

ORCID-Profile: Marit M Melssen, Craig L Slingluff

Förderung

  • NIH HHS
  • NCI NIH HHS
  • Cancer Research Institute
  • NCI F99/K00 Predoctoral to Postdoctoral Transition Award
  • Rebecca Clary Harris Fellowship
  • Barncancerfonden
  • NIH Director's Early Independence Award DP5
  • U.S. Public Health Service

Zitieren

APA

Melssen, M. M., Sheybani, N. D., Leick, K. M., & Slingluff, C. L. (2023). Barriers to immune cell infiltration in tumors. Journal for ImmunoTherapy of Cancer, 11(4), e006401. https://doi.org/10.1136/jitc-2022-006401

Vancouver

Melssen MM, Sheybani ND, Leick KM, Slingluff CL. Barriers to immune cell infiltration in tumors. Journal for ImmunoTherapy of Cancer. 2023;11(4):e006401. doi:10.1136/jitc-2022-006401

BibTeX
@article{Melssen2023,
  author = {Melssen, Marit M and Sheybani, Natasha D and Leick, Katie M and Slingluff, Craig L},
  title = {Barriers to immune cell infiltration in tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {4},
  pages = {e006401},
  doi = {10.1136/jitc-2022-006401}
}
Kostenlos starten →